The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
LMTK3 to regulate the translation of oncogenic KIT in GIST regardless of imatinib sensitivity.
 
Lillian Rose Klug
No Relationships to Disclose
 
Amber Bannon
No Relationships to Disclose
 
Nathalie Javidi-Sharifi
No Relationships to Disclose
 
Ajia Town
No Relationships to Disclose
 
William H Fleming
No Relationships to Disclose
 
Judy VanSlyke
No Relationships to Disclose
 
Linda Musil
No Relationships to Disclose
 
Jonathan A. Fletcher
Consulting or Advisory Role - ARIAD; Bayer; Lilly
Research Funding - AstraZeneca
Patents, Royalties, Other Intellectual Property - Novartis - Imatinib
 
Jeffrey Tyner
Consulting or Advisory Role - Leap Oncology
Research Funding - Aptose Biosciences; Array BioPharma; AstraZeneca/MedImmune; Constellation Pharmaceuticals; Genentech; Incyte; Janssen; Seagen; Takeda
 
Michael C. Heinrich
Stock and Other Ownership Interests - MolecularMD
Honoraria - Novartis
Consulting or Advisory Role - ARIAD; Bayer; Blueprint Medicines; Deciphera; MolecularMD; Novartis; Pfizer
Research Funding - ARIAD (Inst); Blueprint Medicines (Inst); Deciphera (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Patent on treatment of GIST-licensed to Novartis (Inst)
Expert Testimony - Novartis